SOURCE: Orgenesis Inc.

Orgenesis Inc.

October 30, 2015 13:19 ET

Orgenesis CEO to Participate in Diabetes Panel at BIO-Europe 2015

Panel of Experts and Leaders in Current Diabetic Care to Discuss the Future Vision of Diabetic Therapy

GERMANTOWN, MD--(Marketwired - Oct 30, 2015) - Vered Caplan, Chairperson and CEO of Orgenesis (OTCQB: ORGS), has been invited to speak on a panel at BIO-Europe 2015 in Munich, Germany. The discussion panel is titled "Focus on Diabetes" and will center on the current landscape, recent developments and trends in the field.

Karin Hehenberger, MD, PhD, a leading expert in the diabetes world, will moderate the panel. Hehenberger is the Founder and CEO of Lyfebulb, which is a patient-centric organization whose mission is to improve the quality of life for people living with chronic disease now.

Industry leaders have been selected to participate with Caplan on the panel. They include: Juliane Bernholz, Lead International Diabetes Partnering, Sanofi; Karin Conde-Knape, Vice President Cardiovascular and Metabolism at Johnson & Johnson Medical; Thomas Landh, Vice President, Senior Principal Scientist Innovation Sourcing, Novo Nordisk; and Brian T. Bloomquist, Senior Director, Diabetes and Endocrine, Global External R&D, Eli Lilly and Company.

"It is an honor to participate on a panel of such high caliber, featuring the companies and individuals who are on the forefront of addressing the research, development and progress on the global effort to better manage and eventually end diabetes," said Vered Caplan, CEO of Orgenesis.

BIO-Europe 2015 will take place Nov. 2-4 at Munich's International Congress Center (ICM) and will include participants spanning the life sciences, pharmaceutical, medical device and technology innovation sectors.

About Orgenesis Inc.
Orgenesis is a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 Diabetes. In pursuit of this goal, the company has developed and patented a novel technology called "cellular trans-differentiation" that turns an insulin-dependent patient's own liver cells into functional insulin producing cells. Orgenesis has proven that, when exposed ex-vivo to certain pancreatic transcription factors and in specific sequence, human adult liver cells can be transformed into fully functional, beta cell-like insulin producing cells (IPCs). After ex-vivo expansion, the IPCs are re-infused via the portal vein of the diabetic patient. In pre-clinical models of Type 1 Diabetes (Non-Obese Diabetic mice), the re-introduced IPCs remain in the liver, effectively respond to glucose challenge and successfully maintain glycemic homeostasis. In the same NOD model, the implanted IPCs were not subject to auto-immune attack or cellular ablation. Orgenesis plans to initiate P1/2 trials in the next 12-18 months. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. For more information, visit www.orgenesis.com.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; that we can develop the technology to turn a small number of cells into a large number of cells; and that we will initiate Phase I and Phase II clinical trials in the near-term. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Orgenesis will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors, including, among others, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing; the ability to pass clinical trials so as to move on to the next phase; our technology may not as well as expected, our ability to retain key employees; our ability to finance development and operations; our ability to satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information